CA3180139A1 - Quinoline compounds and compositions for inhibiting ezh2 - Google Patents
Quinoline compounds and compositions for inhibiting ezh2Info
- Publication number
- CA3180139A1 CA3180139A1 CA3180139A CA3180139A CA3180139A1 CA 3180139 A1 CA3180139 A1 CA 3180139A1 CA 3180139 A CA3180139 A CA 3180139A CA 3180139 A CA3180139 A CA 3180139A CA 3180139 A1 CA3180139 A1 CA 3180139A1
- Authority
- CA
- Canada
- Prior art keywords
- amino
- chloro
- oxetan
- cyclohexyl
- methylquinolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/108213 | 2020-08-10 | ||
| CN2020108213 | 2020-08-10 | ||
| PCT/CN2021/111910 WO2022033492A1 (en) | 2020-08-10 | 2021-08-10 | Quinoline compounds and compositions for inhibiting ezh2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3180139A1 true CA3180139A1 (en) | 2022-02-17 |
Family
ID=77520462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3180139A Pending CA3180139A1 (en) | 2020-08-10 | 2021-08-10 | Quinoline compounds and compositions for inhibiting ezh2 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12473273B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4041725B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7768880B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230051116A (cg-RX-API-DMAC10.html) |
| CN (2) | CN114555589B (cg-RX-API-DMAC10.html) |
| AR (1) | AR123185A1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021323828B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3180139A1 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2985111T3 (cg-RX-API-DMAC10.html) |
| IL (1) | IL297332B2 (cg-RX-API-DMAC10.html) |
| TW (1) | TWI910207B (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022033492A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR123185A1 (es) | 2020-08-10 | 2022-11-09 | Novartis Ag | Compuestos y composiciones para inhibir ezh2 |
| PE20241731A1 (es) * | 2022-02-01 | 2024-08-19 | Lilly Co Eli | Procesos para la preparacion de degradadores selectivos del receptor de estrogeno |
| CN117384153A (zh) * | 2022-07-12 | 2024-01-12 | 上海赛岚生物科技有限公司 | 一类甲基转移酶抑制剂及其用途 |
| CN118515653B (zh) * | 2024-07-23 | 2024-12-10 | 西湖制药(杭州)有限公司 | 一种ezh2特异性抑制剂及其制备方法和用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
| EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
| JP2002532415A (ja) | 1998-12-16 | 2002-10-02 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤による関節炎の治療 |
| AU7349801A (en) | 2000-07-19 | 2002-01-30 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| CA2478065C (en) | 2002-03-08 | 2013-01-08 | Eisai Co. Ltd. | Macrocyclic compounds useful as pharmaceuticals |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| SE0202134D0 (sv) * | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Therapeutic agents |
| JP2006124387A (ja) | 2004-09-30 | 2006-05-18 | Taisho Pharmaceut Co Ltd | 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| MX2008002114A (es) | 2005-07-21 | 2008-04-17 | Ardea Biosciences Inc | Inhibidores de n-(arilamino)-sulfonamida de mek. |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| BRPI0816769A2 (pt) | 2007-09-12 | 2016-11-29 | Hoffmann La Roche | combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso |
| WO2009055730A1 (en) | 2007-10-25 | 2009-04-30 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| WO2012068589A2 (en) * | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| AP2016009605A0 (en) * | 2014-06-17 | 2016-12-31 | Pfizer | Substituted dihydroisoquinolinone compounds |
| JP2019524872A (ja) * | 2016-06-20 | 2019-09-05 | ノバルティス アーゲー | 癌の治療に有用なイミダゾピリミジン化合物 |
| WO2018195450A1 (en) | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
| CN109912576B (zh) * | 2019-03-20 | 2021-11-19 | 华东理工大学 | 环状或螺环二胺类嘧啶-异羟肟酸及其用途 |
| DK4034535T3 (da) * | 2019-09-26 | 2026-04-07 | Novartis Ag | Aza-quinolinforbindelser og anvendelser deraf |
| AR123185A1 (es) | 2020-08-10 | 2022-11-09 | Novartis Ag | Compuestos y composiciones para inhibir ezh2 |
-
2021
- 2021-08-09 AR ARP210102216A patent/AR123185A1/es unknown
- 2021-08-10 IL IL297332A patent/IL297332B2/en unknown
- 2021-08-10 KR KR1020227019646A patent/KR20230051116A/ko active Pending
- 2021-08-10 US US17/919,490 patent/US12473273B2/en active Active
- 2021-08-10 TW TW110129535A patent/TWI910207B/zh active
- 2021-08-10 CA CA3180139A patent/CA3180139A1/en active Pending
- 2021-08-10 WO PCT/CN2021/111910 patent/WO2022033492A1/en not_active Ceased
- 2021-08-10 JP JP2022530800A patent/JP7768880B2/ja active Active
- 2021-08-10 EP EP21762334.7A patent/EP4041725B1/en active Active
- 2021-08-10 CN CN202180005903.7A patent/CN114555589B/zh active Active
- 2021-08-10 ES ES21762334T patent/ES2985111T3/es active Active
- 2021-08-10 AU AU2021323828A patent/AU2021323828B2/en active Active
- 2021-08-10 CN CN202411371645.6A patent/CN119431341A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR123185A1 (es) | 2022-11-09 |
| TWI910207B (zh) | 2026-01-01 |
| US20230167100A1 (en) | 2023-06-01 |
| JP7768880B2 (ja) | 2025-11-12 |
| EP4041725A1 (en) | 2022-08-17 |
| WO2022033492A1 (en) | 2022-02-17 |
| KR20230051116A (ko) | 2023-04-17 |
| US12473273B2 (en) | 2025-11-18 |
| JP2023538159A (ja) | 2023-09-07 |
| AU2021323828A1 (en) | 2022-05-19 |
| CN119431341A (zh) | 2025-02-14 |
| IL297332B1 (en) | 2025-10-01 |
| ES2985111T3 (es) | 2024-11-04 |
| IL297332A (en) | 2022-12-01 |
| EP4041725B1 (en) | 2024-03-27 |
| CN114555589B (zh) | 2024-10-25 |
| CN114555589A (zh) | 2022-05-27 |
| IL297332B2 (en) | 2026-02-01 |
| TW202220979A (zh) | 2022-06-01 |
| AU2021323828B2 (en) | 2026-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6736559B2 (ja) | トリアゾロピリミジン化合物およびその使用 | |
| CN109906224B (zh) | 三唑吡啶化合物及其应用 | |
| EP4041725B1 (en) | Quinoline compounds and compositions for inhibiting ezh2 as a treatment for cancer diseases | |
| EP4034535B1 (en) | Aza-quinoline compounds and uses thereof | |
| CA3145864A1 (en) | Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof | |
| HK40080941A (en) | Quinoline compounds and compositions for inhibiting ezh2 as a treatment for cancer diseases | |
| HK40080941B (en) | Quinoline compounds and compositions for inhibiting ezh2 as a treatment for cancer diseases | |
| HK40117897A (en) | Compounds and compositions for inhibiting ezh2 | |
| CN120530116A (zh) | Ret-ldd蛋白抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240729 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240729 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250702 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250702 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250702 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250702 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250909 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250909 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260526 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260728 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260728 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260804 |